Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain
Nov 1, 2016, 00:00
10.1016/j.jval.2016.09.1285
https://www.valueinhealthjournal.com/article/S1098-3015(16)32651-1/fulltext
Title :
Cost Per Responder of Apremilast Versus Infliximab Biosimilar, Etanercept, Adalimumab, Ustekinumab and Secukinumab in Patients with Moderate to Severe Psoriasis in Spain
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(16)32651-1&doi=10.1016/j.jval.2016.09.1285
First page :
A569
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
1210